Consano Bio raises $15M to advance chronic sciatica therapy
What's the deal? Consano BioDealroom has a profile for this one. Try Dealroom →, a clinical-stage biotech based in Burlington, Massachusetts, has raised more than $15 million in an oversubscribed early-stage financing. A syndicate of accredited private investors backed the round, which the company announced on October 5, 2026.
Where the money goes: Proceeds will fund completion of Consano's Phase 1 trial of C-1101, its lead investigational therapy for chronic painful lumbosacral radiculopathy (LSR), or chronic sciatica. The study is enrolling patients in Australia and the US, with enrollment expected to wrap in early 2027 and clinical data due in the first half of that year.
What C-1101 does: It is a platelet-derived multi-protein biologic delivered via epidural injection, designed to curb inflammation and stimulate cellular repair at the site of nerve injury. In August 2026, the US Food and Drug Administration (FDA) granted it Fast Track designation for treating LSR.
Why now? There are no FDA-approved drugs for chronic sciatica, leaving patients with treatments that offer only temporary relief. Low back pain is the leading cause of years lived with disability in the US and accounts for an estimated $135 billion in annual healthcare spending — more than any other condition — while also driving opioid use.
The endgame: Including this round, Consano has raised more than $45 million since its founding three years ago. Chief executive officer Andrew Hall called C-1101 "a new category of disease-modifying biologics," adding that "LSR is where we begin, and we believe the potential of this approach extends well beyond a single condition."
The signal: At more than $15 million, the round lands in the top 10% of early-stage health venture deals in the US by size. The backing points to investor appetite for therapies targeting large, underserved pain markets where no approved drug exists.
Read more: prnewswire.com
Image credit: Consano Bio
